{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:48:42Z","timestamp":1779263322407,"version":"3.51.4"},"reference-count":116,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1160,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/annonc\/mdw242","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T03:50:30Z","timestamp":1466653830000},"page":"1696-1705","source":"Crossref","is-referenced-by-count":60,"title":["The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"A.A.","family":"Clancy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Spaans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.I.","family":"Weberpals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw242_bb0010","unstructured":"Cancer Research UK Vulval cancer\u2014UK incidence statistics. http:\/\/info.cancerresearchuk.org\/ cancerstats\/types\/vulva\/incidence\/#Worldwide (4 June 2010, date last accessed)."},{"key":"10.1093\/annonc\/mdw242_bb0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/ajo.12241","article-title":"Genetic and epigenetic variation in vulvar cancer: current research and future clinical practice","volume":"54","author":"McWhirter","year":"2014","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1093\/annonc\/mdw242_bb0020","first-page":"136","article-title":"Vulvar cancer as a target for molecular medicine","volume":"3","author":"Klemba","year":"2011","journal-title":"Front Biosci"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdw242_bb0025","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Foreman","year":"2012","journal-title":"Vaccine"},{"key":"10.1093\/annonc\/mdw242_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.arcmed.2009.06.001","article-title":"HPV-related carcinogenesis: basic concepts, viral types and variants","volume":"40","author":"Lizano","year":"2009","journal-title":"Arch Med Res"},{"key":"10.1093\/annonc\/mdw242_bb0035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ygyno.2003.11.052","article-title":"Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma","volume":"92","author":"Pinto","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13027-015-0008-y","article-title":"Global availability of data on HPV genotype\u2014distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females","volume":"10","author":"Wagner","year":"2015","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdw242_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.11691","article-title":"Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins","volume":"109","author":"Duensing","year":"2004","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1093\/annonc\/mdw242_bb0050","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"Munger","year":"2004","journal-title":"J Virol"},{"issue":"13","key":"10.1093\/annonc\/mdw242_bb0055","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2010.28.2186","article-title":"Human papillomavirus as a therapeutic target in human cancer","volume":"29","author":"Hellner","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2013.05.041","article-title":"Etiology of vulvar cancer will impact on treatment options and therapy outcome: two major pathways of vulvar cancer","author":"Regauer","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bjc.6600677","article-title":"Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma","volume":"88","author":"Rosenthal","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1133::AID-CNCR17>3.0.CO;2-T","article-title":"p53 protein expression in squamous cell carcinoma of the vulva","volume":"85","author":"Scheistroen","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0075","first-page":"473","article-title":"Value of p53, urokinase plasminogen activator, PAI-1 and Ki-67 in vulvar carcinoma","volume":"121","author":"Hoffmann","year":"1999","journal-title":"Zentralbl Gynakol"},{"issue":"8","key":"10.1093\/annonc\/mdw242_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000454","article-title":"Squamous cell carcinoma of the vulva: a subclassification of 97 cases by clinicopathologic, immunohistochemical, and molecular features (p16, p53 and EGFR)","volume":"39","author":"Dong","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdw242_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000182","article-title":"Biomarkers p16, and p53 predict recurrence and survival in early stage squamous cell carcinoma of the vulva","volume":"20","author":"Hay","year":"2016","journal-title":"J Low Genit Tract Dis"},{"key":"10.1093\/annonc\/mdw242_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/PGP.0b013e3182184c7a","article-title":"Role of TP mutations in vulvar carcinomas","volume":"30","author":"Choschzick","year":"2011","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1242\/jcs.03362","article-title":"MDMX: from bench to beside","volume":"120","author":"Marine","year":"2007","journal-title":"J Cell Sci"},{"key":"10.1093\/annonc\/mdw242_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.bjc.6690318","article-title":"In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases","volume":"80","author":"Emanuels","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0110","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4161\/cbt.2.6.679","article-title":"Role of the retinoblastoma family in gynecological cancer","volume":"2","author":"Sanseverino","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdw242_bb0115","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jcp.24329","article-title":"RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis","volume":"228","author":"Di Fiore","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1093\/annonc\/mdw242_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3567","article-title":"Molecular mechanisms underlying RB protein function","volume":"14","author":"Dick","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1093\/annonc\/mdw242_bb0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/gyno.1997.4914","article-title":"Expression of p16INK4 and retinoblastoma protein Rb in vulvar lesions of Chinese women","volume":"68","author":"Chan","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/1471-2407-11-463","article-title":"Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study","volume":"11","author":"Samartzis","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.28142","article-title":"Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway","author":"Holzinger","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0140","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1158\/0008-5472.CAN-03-3739","article-title":"Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells","volume":"64","author":"Psyrri","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00004347-199907000-00001","article-title":"Squamous cell carcinoma of the vulva: study of ploidy, HPV, p53, and pRb","volume":"18","author":"Lerma","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2013.01.008","article-title":"Cell cycle-regulatory cyclins and their deregulation in oral cancer","author":"Mishra","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1278-3218(01)00087-7","article-title":"Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology","volume":"5","author":"Viallard","year":"2001","journal-title":"Cancer Radiother"},{"key":"10.1093\/annonc\/mdw242_bb0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ygyno.2005.03.025","article-title":"Cyclins D1, D3, E, and A in vulvar carcinoma patients","volume":"97","author":"Knopp","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1525-1438.2001.01039.x","article-title":"Cyclin D1 and retinoblastoma protein in vulvar cancer and adjacent lesions","volume":"11","author":"Rolfe","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0170","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.humpath.2011.11.014","article-title":"Role of cyclin D1 amplification and expression in vulvar carcinomas","volume":"43","author":"Choschzick","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/jclinpath-2013-201920","article-title":"Fascin and cyclin D1 immunoreactivity in non-neoplastic vulvar squamous epithelium, vulvar intraepithelial neoplasia and invasive squamous carcinoma: correlation with Ki67 and p16 protein expression","volume":"67","author":"Stewart","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0180","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/hupa.2002.129415","article-title":"Alterations of the p16\/Rb\/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus","volume":"33","author":"Lerma","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF03261895","article-title":"Cyclin-dependent kinase modulators and cancer therapy","volume":"26","author":"Gallorini","year":"2012","journal-title":"BioDrugs"},{"key":"10.1093\/annonc\/mdw242_bb0190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/01.pgp.0000130108.03231.89","article-title":"Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva","volume":"23","author":"Santos","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1479-5876-10-150","article-title":"Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside","volume":"10","author":"de Melo Maia","year":"2012","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdw242_bb0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/pgp.0b013e3180555999","article-title":"Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity","volume":"26","author":"Brustmann","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2008.07.038","article-title":"Decreased survival in EGFR gene amplified vulvar carcinoma","volume":"111","author":"Growdon","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2012.06.028","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw242_bb0215","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/gyno.1997.4660","article-title":"Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival","volume":"65","author":"Johnson","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdw242_bb0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2006.07.035","article-title":"EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction","volume":"104","author":"Oonk","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdw242_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jcp-2010-079806","article-title":"EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome","volume":"65","author":"Woelber","year":"2012","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdw242_bb0230","first-page":"381","article-title":"Expression of epidermal growth factor receptor and HER-2\/neu in normal and neoplastic cervix, vulva, and vagina","volume":"76","author":"Berchuck","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdw242_bb0235","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","article-title":"The biology of stem cell factor and its receptor C-kit","volume":"31","author":"Ashman","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1093\/annonc\/mdw242_bb0240","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1440-1827.1996.tb03571.x","article-title":"Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells","volume":"46","author":"Tsujimura","year":"1996","journal-title":"Pathol Int"},{"key":"10.1093\/annonc\/mdw242_bb0245","first-page":"3049","article-title":"Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors","volume":"54","author":"Inoue","year":"1994","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0250","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2007.11.8984","article-title":"Biology of interactions: antiepidermal growth factor receptor agents","volume":"25","author":"Harari","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/GCO.0b013e328011e6a2","article-title":"New agents in development for breast cancer","volume":"19","author":"Gao","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1093\/annonc\/mdw242_bb0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1078-0432.CCR-06-2167","article-title":"Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder","volume":"13","author":"Wang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0265","unstructured":"Q Wei, Y Shui, S Zheng et al. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: implications for targeted radionuclide therapy. Oncol Rep25: 3\u201311."},{"key":"10.1093\/annonc\/mdw242_bb0270","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/ijc.22355","article-title":"Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer","volume":"120","author":"Reimers","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0275","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1634\/theoncologist.2009-0054","article-title":"The role of EGFR inhibition in the treatment of non-small cell lung cancer","volume":"14","author":"Ray","year":"2009","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw242_bb0280","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejca.2006.09.025","article-title":"EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil","volume":"43","author":"Na","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0285","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jcp.2008.057240","article-title":"A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice","volume":"62","author":"Knopp","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdw242_bb0290","first-page":"1731","article-title":"TGF-alpha, c-erbB-2 expression and neoangiogenesis in vulvar squamous cell carcinoma","volume":"25","author":"Hantschmann","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0295","first-page":"1115","article-title":"Expression of transforming growth factor alpha mRNA in benign and malignant tissues derived from gynecologic patients with various proliferative conditions","volume":"12","author":"Xynos","year":"1992","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0300","first-page":"844","article-title":"Vascular endothelial growth factor: expression in human vulvar neoplastic and nonneoplastic tissues","volume":"41","author":"Doldi","year":"1996","journal-title":"J Reprod Med Obstet Gynecol"},{"key":"10.1093\/annonc\/mdw242_bb0305","first-page":"2806","article-title":"Serum concentrations of vascular endothelial growth factor in vulvar cancer","volume":"5","author":"Hefler","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0310","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.3390\/ijms14059338","article-title":"Biomarkers for anti-angiogenic therapy in cancer","volume":"14","author":"Wehland","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1093\/annonc\/mdw242_bb0315","first-page":"609","article-title":"Role of angiogenesis in benign, premalignant and malignant vulvar lesions","volume":"45","author":"MacLean","year":"2000","journal-title":"J Reprod Med Obstet Gynecol"},{"key":"10.1093\/annonc\/mdw242_bb0320","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2007.05.007","article-title":"The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva","volume":"106","author":"Raspollini","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0325","first-page":"609","article-title":"Role of angiogenesis in benign, premalignant and malignant vulvar lesions","volume":"45","author":"MacLean","year":"2000","journal-title":"J Reprod Med Obstet Gynecol"},{"key":"10.1093\/annonc\/mdw242_bb0330","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2007.05.007","article-title":"The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva","volume":"106","author":"Raspollini","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0335","first-page":"3853","article-title":"Angiogenesis in benign, pre-malignant and malignant vulvar lesions","volume":"22","author":"Bamberger","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw242_bb0340","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1006\/gyno.1996.4582","article-title":"Angiogenesis in vulvar intraepithelial neoplasia","volume":"64","author":"Bancher-Todesca","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0345","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/gyno.1996.0307","article-title":"Influence of microvessel density and vascular permeability factor\/vascular endothelial growth factor expression on prognosis in vulvar cancer","volume":"63","author":"Obermair","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdw242_bb0350","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/his.12034","article-title":"Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma","volume":"62","author":"Del Pino","year":"2013","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdw242_bb0355","first-page":"397","article-title":"Vulval squamous cell carcinoma occurring on a background of differentiated vulvar intraepithelial neoplasia is more likely to recur: a review of 154 cases","volume":"53","author":"Eva","year":"2008","journal-title":"J Reprod Med"},{"key":"10.1093\/annonc\/mdw242_bb0360","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/IGC.0b013e3181bc1bf4","article-title":"Differentiated-type vulval intraepithelial neoplasia has a high-risk association with vulval squamous cell carcinoma","volume":"20","author":"Van de Nieuwenhof","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0365","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ijc.25400","article-title":"Association between toll-like receptor expression and human papillomavirus type 16 persistence","volume":"128","author":"Daud","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1440-1711.2004.01291.x","article-title":"Activation of dendritic cells by human papillovirus-like particles through TLR4 can NF-kappa B-mediated signalling, moderated by TGF-beta","volume":"83","author":"Yan","year":"2005","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"10.1093\/annonc\/mdw242_bb0375","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ijc.28364","article-title":"Genetic variation in the TLR and NF-kB pathways and cervical and vulvar cancer risk: a population-based case control study","volume":"134","author":"Bodelon","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0380","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2014.11.002","article-title":"Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature","volume":"136","author":"Trietsch","year":"2015","journal-title":"Gyne Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdw242_bb0385","doi-asserted-by":"crossref","first-page":"e93451","DOI":"10.1371\/journal.pone.0093451","article-title":"Designing a high-throughput somatic mutation profiling panel specifically for gynecological cancers","volume":"9","author":"Spaans","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdw242_bb0390","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2014.07.094","article-title":"CDKN2A (16) and HRAS are frequently mutated in vulvar squamous cell carcinoma","volume":"135","author":"Trietsch","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0395","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0400","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e13600","article-title":"A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed\/refractory solid tumors","author":"Kurzrock","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdw242_bb0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbozone (3-AP, NSCL#663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecologic Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdw242_bb0410","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC# 663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl","key":"10.1093\/annonc\/mdw242_bb0415","first-page":"S169","article-title":"The molecular target of rapamycin (mTOR) as a therapeutic target against cancer","volume":"2","author":"Mita","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdw242_bb0420","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1593\/neo.13432","article-title":"Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition","volume":"15","author":"Coppock","year":"2013","journal-title":"Neoplasia"},{"key":"10.1093\/annonc\/mdw242_bb0425","article-title":"Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer","author":"Schrader","year":"2013","journal-title":"Eur Urol"},{"issue":"8","key":"10.1093\/annonc\/mdw242_bb0430","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring P1K3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdw242_bb0435","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2014.02.017","article-title":"mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review","volume":"133","author":"Husseinzadeh","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdw242_bb0440","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-008-0921-5","article-title":"SNS-032 a potent and selective CDK 2,7 and 9 inhibitor that drives target modulation in patient samples","volume":"64","author":"Conroy","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1093\/annonc\/mdw242_bb0445","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bmc.2010.01.042","article-title":"Optimization of 6,6-dimethyl pyrrolo[3,4-c] pyrazoles: identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing","volume":"18","author":"Brasca","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"10.1093\/annonc\/mdw242_bb0450","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/leu.2013.194","article-title":"Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers p53-dependent and independent anti-multiple myeloma activity through inhibition of transcription of CDKs","volume":"27","author":"Cirstea","year":"2013","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdw242_bb0455","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4161\/cc.10.6.15075","article-title":"A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin dependent kinases (CDK 1,4) reveals unexpected hepatoxicity in patients with solid tumors","volume":"10","author":"Massard","year":"2011","journal-title":"Cell Cycle"},{"issue":"9","key":"10.1093\/annonc\/mdw242_bb0460","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/annonc\/mdq734","article-title":"A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdw242_bb0465","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3109\/10428194.2013.783911","article-title":"Emerging drug profile: cyclin-dependent kinase inhibitors","volume":"54","author":"Blachly","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw242_bb0470","article-title":"New targeted anti-CDK4\/6 peptide MM-D37K","author":"Konstantinovich Bozhenko","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdw242_bb0475","article-title":"Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor","volume":"30","author":"Rose","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0480","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5506","article-title":"An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P\/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer","volume":"33","author":"Oza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdw242_bb0485","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.12-7-840","article-title":"Erlotinib in non-small cell lung cancer treatment: current status and future development","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw242_bb0490","first-page":"423","article-title":"A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor","volume":"32","author":"Bacha","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0495","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2007.05.006","article-title":"Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva","volume":"106","author":"Olawaiye","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0500","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1525-1438.2007.01145.x","article-title":"Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab","volume":"18","author":"Richard","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdw242_bb0505","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2165\/11591410-000000000-00000","article-title":"Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma","volume":"71","author":"Escudier","year":"2011","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdw242_bb0510","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/0253-7613.81497","article-title":"Promising molecular targeted therapies in breast cancer","volume":"43","author":"Munagala","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"10.1093\/annonc\/mdw242_bb0515","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/CAD.0b013e328345ffa4","article-title":"Combining molecular targeted therapies: clinical experience","volume":"22","author":"Pivot","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdw242_bb0520","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0525","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2011.11.042","article-title":"A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia","volume":"125","author":"Mackay","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0530","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw242_bb0535","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1093\/annonc\/mdw242_bb0540","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of human papillomavirus-related disease","volume":"30","author":"Stern","year":"2012","journal-title":"Vaccine"},{"key":"10.1093\/annonc\/mdw242_bb0545","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.169.1.350","article-title":"Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides","volume":"169","author":"Zwaveling","year":"2002","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdw242_bb0550","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw242_bb0555","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1093\/annonc\/mdw242_bb0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/1078-0432.CCR-05-1178","article-title":"Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine","volume":"12","author":"Haas","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1093\/annonc\/mdw242_bb0565","first-page":"701","article-title":"Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2\/3. Results of a pilot study","volume":"47","author":"Van Seters","year":"2002","journal-title":"J Reprod Med"},{"issue":"2","key":"10.1093\/annonc\/mdw242_bb0570","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2007.06.003","article-title":"Topical imiquimod can reverse vulvar intraepithelial neoplasia; a randomized double-blinded study","volume":"107","author":"Mathiesen","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdw242_bb0575","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw242_bb0580","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2662","article-title":"A dual P13K\/mTOR inhibitor as a potential therapeutic option in vulvar cancer","volume":"75","author":"Rodrigues","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdw242_bb0585","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2014.01.008","article-title":"MEK 1\/2 inhibitors in the treatment of gynecological malignancies","volume":"133","author":"Miller","year":"2014","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/9\/1696\/6678983\/mdw242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:05:08Z","timestamp":1656727508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419358740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0923753419358740"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw242","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}